AR106591A1 - Derivados de indolin-2-ona - Google Patents
Derivados de indolin-2-onaInfo
- Publication number
- AR106591A1 AR106591A1 ARP160103366A ARP160103366A AR106591A1 AR 106591 A1 AR106591 A1 AR 106591A1 AR P160103366 A ARP160103366 A AR P160103366A AR P160103366 A ARP160103366 A AR P160103366A AR 106591 A1 AR106591 A1 AR 106591A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- group
- diseases
- disease
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a derivados de indolin-2-ona de fórmula general (1) en donde A es fenilo o un grupo heteroarilo de seis miembros, que contiene uno o dos átomos de N, seleccionados entre los restos del grupo de fórmulas (2); R¹ es S(O)₂-alquilo inferior, S(O)₂NR⁴R⁵, S(O)₂-cicloalquilo, S-alquilo inferior o S(O)₂-azetidin-1-ilo; R⁴ y R⁵ son independientemente el uno del otro, hidrógeno, alquilo inferior o (CH₂)₂OCH₃; o el grupo A-R¹ puede formar junto con dos átomos de carbono colindantes a partir del grupo A un anillo condensado adicional, seleccionado entre los restos del grupo de fórmulas (3); R² es hidrógeno o cicloalquilo; R³ es metilo o halógeno; n es 1 ó 2; X es N, N⁺O⁻ o CH; - - - - la línea de puntos puede no ser nada o -CH₂-; así como con una sal farmacéuticamente aceptable del mismo, con una mezcla racémica, o con su enantiómero correspondiente y/o isómero óptico y/o estereoisómero del mismo. Los compuestos pueden usarse en el tratamiento de enfermedades del SNC relacionados con los síntomas positivos (psicosis) y negativos de la esquizofrenia, abuso de sustancias, el alcohol y la drogadicción, los trastornos obsesivo-compulsivos, trastornos cognitivos, trastornos bipolares, trastornos del humor, la depresión mayor, el tratamiento resistente depresión, trastornos de ansiedad, la enfermedad del Alzheimer, autismo, enfermedad de Parkinson, dolor crónico, trastorno limítrofe de la personalidad, enfermedades neurodegenerativas, trastornos del sueño, síndrome de fatiga crónica, rigidez, enfermedades inflamatorias, el asma, la enfermedad de Huntington, el TDAH, la esclerosis lateral amiotrófica, los efectos en artritis, enfermedades autoinmunes, infecciones víricas y fúngicas, enfermedades cardiovasculares, inflamatorias oftalmología y enfermedades de la retina y problemas de equilibrio, epilepsia y trastornos del neurodesarrollo con epilepsia comórbida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15193437 | 2015-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106591A1 true AR106591A1 (es) | 2018-01-31 |
Family
ID=54476851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103366A AR106591A1 (es) | 2015-11-06 | 2016-11-04 | Derivados de indolin-2-ona |
Country Status (7)
Country | Link |
---|---|
US (1) | US10377746B2 (es) |
EP (1) | EP3371170B1 (es) |
JP (1) | JP6857651B2 (es) |
CN (1) | CN108137555B (es) |
AR (1) | AR106591A1 (es) |
TW (1) | TWI677495B (es) |
WO (1) | WO2017076932A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns疾患の処置に有用なインドリン−2−オン誘導体 |
CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
EP3371169B1 (en) | 2015-11-06 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
PE20181885A1 (es) | 2015-11-06 | 2018-12-07 | Hoffmann La Roche | Derivados de indolin-2-ona |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
TW251284B (es) | 1992-11-02 | 1995-07-11 | Pfizer | |
DE4427648A1 (de) | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
AU2494300A (en) | 1999-01-07 | 2000-07-24 | American Home Products Corporation | 3,4-dihydro-2h-benzo(1,4)oxazine derivatives |
ATE311879T1 (de) | 2000-06-29 | 2005-12-15 | Neurosearch As | Verwendung von 3-substituierten oxidinolderivaten als kcnq kaliumkanalmodulatoren |
WO2004060902A2 (en) | 2002-12-31 | 2004-07-22 | John K Buolamwini | Novel nucleoside transport inhibitors |
KR20070011552A (ko) * | 2004-05-11 | 2007-01-24 | 에지스 지오기스제르기아르 엔와이알티. | 5-ht7 수용체 활성제로서 알킬 옥스인돌의 피리딘유도체 |
US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
EP2032135A2 (en) | 2006-06-26 | 2009-03-11 | Helicon Therapeutics, Inc. | Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist |
WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
WO2008080970A1 (en) | 2006-12-30 | 2008-07-10 | Abbott Gmbh & Co. Kg | Substituted oxindole derivative and its use as a vasopressin receptor ligand |
EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
KR101706877B1 (ko) | 2012-09-13 | 2017-02-15 | 에프. 호프만-라 로슈 아게 | Cns 장애의 치료를 위한 2-옥소-2,3-다이하이드로-인돌 |
CN105308039B (zh) | 2013-06-19 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 吲哚满-2-酮或吡咯并-吡啶/嘧啶-2-酮衍生物 |
RU2697512C2 (ru) * | 2014-05-22 | 2019-08-15 | Ф. Хоффманн-Ля Рош Аг | Производные индолин-2-она и 1,3-дигидро-пирроло[3,2-c]пиридин-2-она |
KR101819433B1 (ko) * | 2014-06-26 | 2018-01-16 | 에프. 호프만-라 로슈 아게 | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 |
CN108137561B (zh) | 2015-11-06 | 2021-03-26 | 豪夫迈·罗氏有限公司 | 二氢吲哚-2-酮衍生物 |
PE20181885A1 (es) | 2015-11-06 | 2018-12-07 | Hoffmann La Roche | Derivados de indolin-2-ona |
EP3371169B1 (en) | 2015-11-06 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives for use in the treatment of cns and related disorders |
JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cns疾患の処置に有用なインドリン−2−オン誘導体 |
-
2016
- 2016-11-03 JP JP2018519913A patent/JP6857651B2/ja active Active
- 2016-11-03 CN CN201680062263.2A patent/CN108137555B/zh active Active
- 2016-11-03 WO PCT/EP2016/076473 patent/WO2017076932A1/en active Application Filing
- 2016-11-03 EP EP16791377.1A patent/EP3371170B1/en active Active
- 2016-11-04 AR ARP160103366A patent/AR106591A1/es unknown
- 2016-11-04 TW TW105135827A patent/TWI677495B/zh active
-
2018
- 2018-05-04 US US15/971,426 patent/US10377746B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10377746B2 (en) | 2019-08-13 |
CN108137555B (zh) | 2021-02-19 |
CN108137555A (zh) | 2018-06-08 |
EP3371170B1 (en) | 2019-07-31 |
WO2017076932A1 (en) | 2017-05-11 |
US20180251455A1 (en) | 2018-09-06 |
TW201726652A (zh) | 2017-08-01 |
JP6857651B2 (ja) | 2021-04-14 |
TWI677495B (zh) | 2019-11-21 |
EP3371170A1 (en) | 2018-09-12 |
JP2018531950A (ja) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502231A1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
AR106590A1 (es) | Derivados de indolin-2-ona | |
AR106589A1 (es) | Derivados de indolin-2-ona | |
AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
AR106591A1 (es) | Derivados de indolin-2-ona | |
EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
AR099047A1 (es) | Derivados etinilo | |
EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc | |
AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
AR089691A1 (es) | Derivados heterociclicos | |
EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
AR104863A1 (es) | Derivados imidazol | |
AR100210A1 (es) | Derivados de piridina con afinidad a taar | |
EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
CO2018013824A2 (es) | Derivados de etinilo | |
AR093372A1 (es) | Derivados de pirazina | |
AR100532A1 (es) | Derivados de indolín-2-ona y 1,3-dihidro-pirrolo[3,2-c]piridín-2-ona | |
MA37895A1 (fr) | Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité | |
AR080102A1 (es) | Compuestos de aril-bencil-amina y su utilizacion en el tratamiento de trastornos mediados por las interacciones de los linfocitos | |
EA201790399A1 (ru) | Способ крупномасштабного производства 1-изопропил-3-{5-[1-(3-метоксипропил)пиперидин-4-ил]-[1,3,4]оксадиазол-2-ил}-1h-индазола оксалата | |
AR062950A1 (es) | Compuestos tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen |